Last reviewed · How we verify
Solriamfetol Oral Tablet [Sunosi]
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor that increases wakefulness by blocking the reuptake of these neurotransmitters in the central nervous system.
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor that increases wakefulness by blocking the reuptake of these neurotransmitters in the central nervous system. Used for Excessive daytime sleepiness in patients with narcolepsy, Excessive daytime sleepiness in patients with obstructive sleep apnea.
At a glance
| Generic name | Solriamfetol Oral Tablet [Sunosi] |
|---|---|
| Also known as | Sunosi |
| Sponsor | Rochester Center for Behavioral Medicine |
| Drug class | Dopamine and norepinephrine reuptake inhibitor |
| Target | Dopamine transporter (DAT) and norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Sleep Medicine |
| Phase | FDA-approved |
Mechanism of action
Solriamfetol works by inhibiting the reuptake of dopamine and norepinephrine, thereby increasing their concentrations in the synaptic space and enhancing neural signaling associated with wakefulness and alertness. This mechanism promotes arousal and reduces excessive daytime sleepiness in patients with narcolepsy and obstructive sleep apnea.
Approved indications
- Excessive daytime sleepiness in patients with narcolepsy
- Excessive daytime sleepiness in patients with obstructive sleep apnea
Common side effects
- Headache
- Insomnia
- Nausea
- Anxiety
- Increased heart rate
- Dry mouth
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: